Drugs / Ametinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05754736 | Dec 2022 → Dec 2023 | non-small cell lung carcinoma | The Second Affiliated Hospital of Shandong First Medical University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06895928 Background | Mar 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ametinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895928 ↗ |
| Known as | Ametinib mesylate | “Ametinib mesylate tablets.” NCT06895928 ↗ |
| Modality | Small molecule | “Third-generation TKI combined with antivascular targeting drug” NCT05754736 ↗ |
| Route | Oral | “Ametinib 110mg po qd” NCT05754736 ↗ |